Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT07159906 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07159906
- Sponsor
- First Affiliated Hospital of Zhejiang University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-08
- Primary completion
- 2027-08-01
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.